Therefore, while our data suggest a broad applicability of PHD inhibitors in AML, further investigations are warranted to identify those AML genomic subgroups that are particularly sensitive to PHD inhibition, singly or in combination with FIH inhibition and venetoclax. The gene discussed is PDC; the disease is acute myeloid leukemia.